BEVACIZUMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 09:42:15 GMT 2025` Edited by `admin` on `Wed Apr 02 09:42:15 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	2S9ZZM9Q9V
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED

Preferred Name

English

BEVACIZUMAB

Official Name

English

bevacizumab [INN]

Common Name

English

RO-4876646

Code

English

BEVACIZUMAB [MART.]

Common Name

English

AVASTIN

Common Name

English

IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL RHUMAB-VEGF .GAMMA.-CHAIN ANTI-HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL RHUMAB-VEGF LIGHT CHAIN, DIMER

Common Name

English

RG-435

Code

English

12-IGG1

Code

English

RHUMAB-

Code

English

BEVACIZUMAB [EMA EPAR]

Common Name

English

BEVACIZUMAB [VANDF]

Common Name

English

Bevacizumab [WHO-DD]

Common Name

English

BEVACIZUMAB [MI]

Common Name

English

BEVACIZUMAB (AVASTIN)

Common Name

English

BEVACIZUMAB [PURPLE BOOK CDER]

Common Name

English

BEVACIZUMAB [JAN]

Common Name

English

PF-06439535 [WHO-DD]

Common Name

English

BEVACIZUMAB [USAN]

Common Name

English

USP MAB 002, MONOCLONAL IGG1 [USP-RS]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

317810

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

FDA ORPHAN DRUG

222906

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

FDA ORPHAN DRUG

512215

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

FDA ORPHAN DRUG

505115

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

FDA ORPHAN DRUG

291709

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

LIVERTOX

NBK548877

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

NDF-RT

N0000178291

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

WHO-ATC

L01XC07

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

NDF-RT

N0000178292

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

EMA ASSESSMENT REPORTS

AVASTIN (AUTHORIZED: OVARIAN NEOPLASMS)

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

FDA ORPHAN DRUG

294409

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

WHO-VATC

QL01XC07

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

FDA ORPHAN DRUG

318010

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

FDA ORPHAN DRUG

193704

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

EMA ASSESSMENT REPORTS

AVASTIN (AUTHORIZED: COLORECTAL NEOPLASMS)

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

EMA ASSESSMENT REPORTS

AVASTIN (AUTHORIZED: CARCINOMA, RENAL CELL)

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

FDA ORPHAN DRUG

317510

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

NCI_THESAURUS

C2496

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

NDF-RT

N0000193543

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

FDA ORPHAN DRUG

216405

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

FDA ORPHAN DRUG

619317

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

NDF-RT

N0000020007

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

NCI_THESAURUS

C129822

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

FDA ORPHAN DRUG

172903

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

EU-Orphan Drug

EU/3/14/1390

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

Code System Code Type Description

RXCUI

253337

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

RxNorm

LACTMED

Bevacizumab

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

CAS

216974-75-3

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

INN

8017

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

DAILYMED

2S9ZZM9Q9V

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

MERCK INDEX

m2464

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

Merck Index

WIKIPEDIA

BEVACIZUMAB

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

FDA UNII

2S9ZZM9Q9V

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

RXCUI

2268037

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

ALTERNATIVE

NCI_THESAURUS

C2039

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

DRUG BANK

DB00112

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

SMS_ID

100000089535

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

RXCUI

2046138

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

ALTERNATIVE

EVMPD

SUB16402MIG

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

MESH

C469428

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

DRUG CENTRAL

4956

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

ChEMBL

CHEMBL1201583

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

RS_ITEM_NUM

1445547

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

IUPHAR

6771

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

HSDB

8080

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

USAN

KK-78

Created by admin on Wed Apr 02 09:42:16 GMT 2025 , Edited by admin on Wed Apr 02 09:42:16 GMT 2025

PRIMARY

Related Record Type Details

Bevacizumab-ADCD

BIOSIMILAR -> PARENT

Amount:

BEVACIZUMAB-AWWB

BIOSIMILAR -> PARENT

Amount:

Q-1101

BIOSIMILAR -> PARENT

Amount:

Bevacizumab-TNJN

BIOSIMILAR -> PARENT

Amount:

Q-1101

TARGET -> ACTIVATOR

Amount:

BEVACIZUMAB BIOSIMILAR (GP-2019)

SUB_CONCEPT->SUBSTANCE

Amount:


					JA0XKI4FW7

HIGH AFFINITY IMMUNOGLOBULIN GAMMA FC RECEPTOR I

TARGET -> AGONIST

BS-503

BIOSIMILAR -> PARENT

BI-695502

SUB_CONCEPT->SUBSTANCE

Amount:

BEVACIZUMAB BIOSIMILAR (GP-2019)

BIOSIMILAR -> PARENT

Amount:

HLX-04

SUB_CONCEPT->SUBSTANCE

Amount:

TRASTUZUMAB-DKST

BIOSIMILAR->REFERENCE PRODUCT

Amount:


					NZN256ZSV8

HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A

TARGET -> INHIBITOR

BEVACIZUMAB-MALY

SUB_CONCEPT->SUBSTANCE

Amount:

BEVACIZUMAB BETA

SUB_CONCEPT->SUBSTANCE

Amount:

BEVACIZUMAB-BVZR

BIOSIMILAR->REFERENCE PRODUCT

Amount:

BEVACIZUMAB-AWWB

SUB_CONCEPT->SUBSTANCE

BS-503

SUB_CONCEPT->SUBSTANCE

Amount:

Bevacizumab-TNJN

SUB_CONCEPT->SUBSTANCE

Amount:

Q-1101

SUB_CONCEPT->SUBSTANCE

Amount:

IBI-305

BIOSIMILAR -> PARENT

Amount:

LY-01008

BIOSIMILAR -> PARENT

Amount:

BEVACIZUMAB-BVZR

SUB_CONCEPT->SUBSTANCE

Amount:

FKB-238

SUB_CONCEPT->SUBSTANCE

Amount:

Bevacizumab-ADCD

SUB_CONCEPT->SUBSTANCE

Amount:

BEVACIZUMAB-BVZR

BIOSIMILAR -> PARENT

Amount:


					2S9ZZM9Q9V

SUB_CONCEPT->SUBSTANCE

Amount:

LY-01008

SUB_CONCEPT->SUBSTANCE

Amount:

BI-695502

BIOSIMILAR -> PARENT

Amount:

IBI-305

SUB_CONCEPT->SUBSTANCE

Amount:

BEVACIZUMAB-AWWB

BIOSIMILAR->REFERENCE PRODUCT

Amount:

HLX-04

BIOSIMILAR -> PARENT

Amount:

Related Record Type Details


					2S9ZZM9Q9V

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL